Latest Conference Articles

January 23rd 2023, 9:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The high concordance rate between gastric and breast cancer HER2 scoring algorithms suggest that either may be used in the metastatic colorectal cancer setting.

January 22nd 2023, 5:06pm

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer.

January 22nd 2023, 4:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

A novel Burning Rock patient-specific prognostic and potential therapeutic marker tracking approach demonstrated improved sensitivity in detecting circulating tumor DNA and identifying molecular residual disease compared with other approaches in patients with colorectal cancer following surgery.

January 22nd 2023, 4:44pm

Gastrointestinal Cancers Symposium (ASCO GI)

Circulating tumor DNA could serve as an ideal biomarker to assess early response in patients with advanced colorectal cancer due to its short half-life compared with other tumor biomarkers, and it could enable the use of adaptive clinical study designs in the future.

January 22nd 2023, 3:56pm

Scott Kopetz, MD, PhD, FACP, discusses the safety lead-in data from the phase 3 BREAKWATER trial in patients with BRBRAF V600E–mutant metastatic colorectal cancer.

January 22nd 2023, 5:59am

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

January 21st 2023, 11:40pm

Gastrointestinal Cancers Symposium (ASCO GI)

Both veliparib plus total neoadjuvant therapy and pembrolizumab plus total neoadjuvant therapy failed to improve short-term outcomes in unselected patients with locally advanced rectal cancer.

January 21st 2023, 11:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

January 21st 2023, 8:07pm

Gastrointestinal Cancers Symposium (ASCO GI)

Newer frontline therapies demonstrated a real-world improvement in survival and responses compared with sorafenib in patients with hepatocellular carcinoma.

January 21st 2023, 6:38pm

Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.

January 21st 2023, 6:13pm

Laura Dawson, MD, FRCPC, discusses results from the phase 3 NRG/RTOG 1112 trial of stereotactic body radiation therapy plus sorafenib compared with sorafenib alone in patients with locally advanced hepatocellular carcinoma.

January 21st 2023, 2:15am

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.

January 21st 2023, 1:55am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.

January 21st 2023, 1:50am

Gastrointestinal Cancers Symposium (ASCO GI)

Tislelizumab monotherapy resulted in favorable health-related quality of life outcomes compared with sorafenib as frontline treatment for patients with unresectable hepatocellular carcinoma.

January 21st 2023, 1:20am

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of stereotactic body radiation therapy to sorafenib led to an improvement in overall survival, progression-free survival, and time to disease progression compared with sorafenib alone in patients with locally advanced, hepatocellular carcinoma.

January 21st 2023, 1:17am

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of nab-paclitaxel to gemcitabine and cisplatin did not result in a statistically significant improvement in overall survival over gemcitabine/cisplatin alone in patients with newly diagnosed, advanced biliary tract cancers.

January 21st 2023, 1:16am

Gastrointestinal Cancers Symposium (ASCO GI)

First-line treatment with the combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin produced a clinically meaningful and statistically significant improvement in overall survival and progression-free survival vs nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase 3 NAPOLI 3 trial.

January 20th 2023, 11:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.

January 20th 2023, 10:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Findings from the phase 2 CISLC-12 study show favorable safety and efficacy signals for patients with unresectable hepatocellular carcinoma treated with the combination of envafolimab, lenvatinib, and transarterial chemoembolization.

January 20th 2023, 9:30pm

Gastrointestinal Cancers Symposium (ASCO GI)

The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.